NIH to Fund Clinical Trials by Type Instead of Disease

by Fitri Anggraini • 9 hours ago
NIH to Fund Clinical Trials by Type Instead of Disease

The National Institutes of Health (NIH) is restructuring its clinical trial funding approach, categorizing it by trial type rather than disease. On November 10, NIH announced that its institutes are collaboratively developing five full Notices of Funding Opportunity (NOFOs) tailored to specific trial types. This shift aims to provide researchers with a unified set of guidelines for each trial category, replacing the previous practice where individual institutes created their own NOFOs with distinct instructions and evaluation criteria.

Streamlined Funding Opportunities

Under the new system, each trial type, feasibility, early to definitive, multisite, pragmatic and implementation, and network trials, will have a single shared NOFO. For instance, a feasibility trial will follow the same NOFO regardless of whether it focuses on cardiology, neurology, or another field. NIH will communicate its priorities through institute, center, and office (ICO) profile pages, strategic plans, and Highlighted Topics, moving away from using NOFOs as the primary means of signaling research interests.

This reform follows NIH’s recent consolidation of career development (K) awards, reclassification of basic experimental studies involving humans, and reduction of active NOFOs from over 800 at the beginning of 2025 to fewer than 500 by year-end. The new NOFOs will apply across all institutes and complement existing parent announcements for clinical trial research project grants (R01) and exploratory/developmental grants (R21). Researchers can continue submitting trials through these established announcements or opt for the new trial-type NOFOs. NIH plans to introduce the new NOFOs gradually.

In May, a National Heart, Lung, and Blood Institute (NHLBI) representative outlined the trial suite at the Society for Clinical Trials meeting. Presentation slides indicated that NIH might release the new NOFOs in late 2026 or early 2027. As of November 12, none have been published.

NIH asserts that these changes will simplify the process for researchers to locate appropriate NOFOs, ensure consistent guidelines for similar trial types, enhance methodological rigor, facilitate co-funding across institutes, and improve internal trial tracking. Institutes will retain the ability to issue targeted trial NOFOs for specific programmatic needs, though the criteria for determining such needs remain unclear.

Although no external groups have publicly endorsed the changes, two NIH institutes have already adopted similar models. The National Center for Complementary and Integrative Health (NCCIH) transitioned most of its trials to a trial-type system in 2017, and NHLBI funded 218 investigator-initiated trials using a comparable set of NOFOs from fiscal 2017 to 2024.

LEAVE A REPLY

Your email address will not be published. Required fields are marked *